Home Business NewsBusiness Astrazeneca commences crucial Covid-19 trial

Astrazeneca commences crucial Covid-19 trial

by LLB Editor
25th Aug 20 12:13 pm

Astrazeneca has confirmed that it has begun a phase one trial of an antibody treatment that could be used to protect people from the coronavirus.

Up to 48 healthy participants in the UK – aged between 18 to 55 years – will take part in the trial which will evaluate the safety and tolerability of the treatment.

“Synthesised in the laboratory, monoclonal antibodies aim to mimic natural antibodies,” stated Astrazeneca. “The treatment has the potential to be given as a preventative option for people exposed to the virus, and to treat and prevent disease progression in patients already infected by the virus.”

Leave a Comment

You may also like


Sign up to our daily news alerts

[ms-form id=1]